Comparative Pharmacology
Head-to-head clinical analysis: TRANDOLAPRIL versus VASOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRANDOLAPRIL versus VASOTEC.
TRANDOLAPRIL vs VASOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trandolapril is a prodrug that is hydrolyzed to its active metabolite trandolaprilat, which inhibits angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and preload/afterload reduction.
Enalaprilat, the active metabolite of enalapril, competitively inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and afterload.
1–2 mg orally once daily; maximum 4 mg once daily.
2.5 to 10 mg orally twice daily; initial dose 5 mg once daily; titrate based on blood pressure response; maximum 40 mg/day.
None Documented
None Documented
Clinical Note
moderateTrandolapril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid."
Clinical Note
moderateTrandolapril + Furosemide
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Furosemide."
Clinical Note
moderateTrandolapril + Bumetanide
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Bumetanide."
Clinical Note
moderateTrandolapril: 6 hours; Trandolaprilat: 24 hours (terminal); effective half-life for ACE inhibition: ~24 hours allowing once-daily dosing
Terminal half-life of enalaprilat is 35-38 hours, with multiple-dose half-life ~11 hours due to prolonged terminal phase; clinical context: once-daily dosing achieves steady-state in 3-4 days.
Renal: 33% (as trandolaprilat); Fecal: 66% (as trandolapril and trandolaprilat); Biliary: minimal
Renal: 60-70% as enalaprilat; fecal: 20-30% as enalaprilat; biliary: minor (<10%).
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor
Trandolapril + Benzydamine
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Benzydamine."